Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]
News [5245]
Articles [128]
Editorials [4]
Conferences [157]
elearning [13]
Making oncology global with the WIN consortium
Dr Josep Tabernero - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Making oncology global with the WIN consortium ( Dr Josep Tabernero - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
25 Apr 2019
The translational element of the WIN consortium
Dr Brian Leyland-Jones - WIN Head of Fundraising Committee
The translational element of the WIN consortium ( Dr Brian Leyland-Jones - WIN Head of Fundraising Committee )
25 Apr 2019
How the WIN consortium achieves its goals
Prof Apostolia-Maria Tsimberidou - MD Anderson Cancer Centre, Houston, USA
How the WIN consortium achieves its goals ( Prof Apostolia-Maria Tsimberidou - MD Anderson Cancer Centre, Houston, USA )
25 Apr 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive...
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1 advanced NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Hong Kong )
18 Apr 2019
Entrectinib in NTRK fusion-positive non-small cell lung cancer
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
Entrectinib in NTRK fusion-positive non-small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )
18 Apr 2019
Using CT imaging to find radiomic signatures in surgically resected NSCLC
Giulia Mazzaschi - University Hospital Parma, Parma, Italy
Using CT imaging to find radiomic signatures in surgically resected NSCLC ( Giulia Mazzaschi - University Hospital Parma, Parma, Italy )
18 Apr 2019
The role of afatinib in patients with EGFR NSCLC
Dr Antonio Passaro - European Institute of Oncology, Milan, Italy
The role of afatinib in patients with EGFR NSCLC ( Dr Antonio Passaro - European Institute of Oncology, Milan, Italy )
18 Apr 2019
ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory...
Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA
ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )
15 Apr 2019
Efficacy and immune correlates of the SRA737 plus LDG regimen in combination...
Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas
Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model ( Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas )
15 Apr 2019
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET...
Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI ( Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA )
15 Apr 2019
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1...
Dr James Gulley - National Cancer Institute, Bethesda, USA
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies ( Dr James Gulley - National Cancer Institute, Bethesda, USA )
15 Apr 2019
Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone...
Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA
Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma ( Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA )
15 Apr 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation